Akebia Ther (AKBA NASDAQ) stock market data APIs
$1.5469
0.08(5.2%)
as of November 20, 2025
Try our APIs with
free plan!
Akebia Ther Financial Data Overview
Price chart is built with
Anychart
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Prev. Close
1.5469
Open
1.6306
High
1.6408
Low
1.5347
52 wk Range
1.52-4.0787
Market Cap
409 M
Shares Outstanding
265 M
Revenue
225 M
EPS
0.002
Beta
0.282
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Akebia Ther (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Akebia Ther data using free add-ons & libraries
Get Akebia Ther Fundamental Data
Akebia Ther Fundamental data includes:
- Net Revenue: 225 M
- EBITDA: 32 246 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.036
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Akebia Ther News
New
Renal Anemia Market Research Report 2025-2035, Competitive Analysis of Amgen, Sandoz, Pfizer, GlaxoSmithKline, Akebia Therapeutics, and Astellas Pharma
Company Logo The global renal anemia market is experiencing significant growth, driven by advancements in therapeutic options, increased diagnostic accuracy, and enhanced healthcare investments in th...
Theravance's Q3 Earnings Surpass Estimates, Revenues Match
Theravance Biopharma TBPH reported third-quarter 2025 adjusted earnings of 4 cents per share against the Zacks Consensus Estimate of a loss of 3 cents. In the year-ago quarter, the company had incurre...
Akebia signals 7x increase in patient access for Vafseo entering 2026 amid operational focus
Earnings Call Insights: Akebia Therapeutics (AKBA) Q3 2025 MANAGEMENT VIEW * John Butler, CEO, highlighted that "through 41 weeks of launch, Vafseo has generated more total prescriptions than any ...
Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Akebia Therapeutics, Inc. Vafseo® (vadadustat) Q3 2025 net product revenues grew to $14.3 million; Q3 2025 total net product revenues were $56.8 million Operational pilot of Vafseo at DaVita expect...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
